<?xml version='1.0' encoding='utf-8'?>
<document id="24122511"><sentence text="Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)."><entity charOffset="49-58" id="DDI-PubMed.24122511.s1.e0" text="veliparib" /></sentence><sentence text="Veliparib (ABT-888) is largely eliminated as parent drug in human urine (70% of the dose)"><entity charOffset="0-9" id="DDI-PubMed.24122511.s2.e0" text="Veliparib" /><entity charOffset="11-18" id="DDI-PubMed.24122511.s2.e1" text="ABT-888" /><pair ddi="false" e1="DDI-PubMed.24122511.s2.e0" e2="DDI-PubMed.24122511.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24122511.s2.e0" e2="DDI-PubMed.24122511.s2.e1" /></sentence><sentence text=" Renal unbound clearance exceeds glomerular filtration rate, suggesting the involvement of transporter-mediated active secretion" /><sentence text=" Clinically relevant pharmacokinetic interactions in the kidney have been associated with OAT1, OAT3, OCT2, MATE1, and MATE2K" /><sentence text=" In the present study, interactions of veliparib with these transporters were investigated"><entity charOffset="39-48" id="DDI-PubMed.24122511.s5.e0" text="veliparib" /></sentence><sentence text=" Veliparib inhibited OAT1, OAT3, OCT2, MATE1, and MATE2K with IC50 values of 1371, 505, 3913, 69" /><sentence text="9, and 69" /><sentence text="5 μM, respectively" /><sentence text=" The clinical unbound maximum plasma concentration of veliparib after single oral dose of 50 mg (0"><entity charOffset="54-63" id="DDI-PubMed.24122511.s9.e0" text="veliparib" /></sentence><sentence text="45 μM) is manyfold lower than IC50 values for OAT1, OAT3, OCT2, MATE1, or MATE2K" /><sentence text=" These results indicate a low potential for drug-drug interaction (DDI) with OAT1/3, OCT2, or MATE1/2K" /><sentence text=" Additional studies demonstrated that veliparib is a substrate of OCT2"><entity charOffset="38-47" id="DDI-PubMed.24122511.s12.e0" text="veliparib" /></sentence><sentence text=" In Oct1/Oct2 double-knockout mice, the plasma exposure of veliparib was increased by 1"><entity charOffset="59-68" id="DDI-PubMed.24122511.s13.e0" text="veliparib" /></sentence><sentence text="5-fold, and the renal clearance was decreased by 1" /><sentence text="8-fold as compared with wild-type mice, demonstrating that organic cation transporters contribute to the renal elimination in vivo" /><sentence text=" In summary, the in vitro transporter data for veliparib predicts minimal potential for an OAT1/3-, OCT2-, and MATE1/2K-mediated DDI given the clinical exposure after single oral dose of 50 mg"><entity charOffset="47-56" id="DDI-PubMed.24122511.s16.e0" text="veliparib" /></sentence><sentence text="" /></document>